We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Randomized controlled trial of landiolol, a short-acting beta-1 adrenergic receptor blocker, illustrating changes in high-molecular weight adiponectin levels after elective percutaneous coronary intervention.
- Authors
Kiyokuni, Masayoshi; Konishi, Masaaki; Saigusa, Yusuke; Iwata, Kiwamu; Nakayama, Naoki; Komura, Naohiro; Sugano, Teruyasu; Ishigami, Tomoaki; Ishikawa, Toshiyuki; Yamanaka, Takeharu; Tamura, Kouichi; Kimura, Kazuo
- Abstract
Adiponectin (APN) has cardioprotective properties and bisoprolol has been reported to increase myocardial APN expression and reduce myocardial damage. Administration of landiolol, which has a higher cardio-selectivity and shorter half-life than bisoprolol, during the percutaneous coronary intervention (PCI) may increase serum APN and high-molecular weight (HMW)-APN, an active form of APN, in patients with stable angina pectoris (SAP). We recruited 70 patients with SAP and randomized them to intravenous landiolol during PCI (N = 35) or control group (N = 35). The primary endpoint was serum APN and HMW-APN level 3 days after PCI. There was no difference in the primary endpoint between the landiolol and control groups (8.93 ± 5.24 vs. 10.18 ± 5.81 μg/mL, p = 0.35 and 3.36 ± 2.75 vs. 4.28 ± 3.13 μg/mL, p = 0.20) for APN and HMW-APN levels, respectively. APN and HMW-APN level were significantly decreased 1 day after PCI [−0.55 ± 0.92 μg/mL (9.87–9.32 μg/mL), p < 0.001 and −0.20 ± 0.45 μg/mL (3.89–3.69 μg/mL), p < 0.001, respectively]. Additionally, the absolute change in HMW-APN was significantly smaller in the landiolol group compared to the control group (−0.08 ± 0.27 vs. −0.31 ± 0.55 μg/mL, p = 0.031). Multiple linear regression analysis showed that use of landiolol was an independent predictor of change in HMW-APN (β = 0.276, p = 0.014). Serum APN and HMW-APN level 3 days after PCI were similar between patients treated with and without landiolol. APN and HMW-APN decreased 1 day after PCI in the SAP and landiolol mitigated decrease in HMW-APN.
- Subjects
PERCUTANEOUS coronary intervention; ADRENERGIC receptors; RANDOMIZED controlled trials; MYOCARDIAL reperfusion; MULTIPLE regression analysis; ANGINA pectoris
- Publication
Heart & Vessels, 2020, Vol 35, Issue 11, p1510
- ISSN
0910-8327
- Publication type
Article
- DOI
10.1007/s00380-020-01637-6